Gender Differences in Exclusion Criteria for Recombinant Tissue-Type Plasminogen Activator

Area of Science:

• Neurology
• Cardiovascular Medicine
• Public Health

Background:

• Recombinant tissue-type plasminogen activator (r-tPA) is a critical treatment for ischemic stroke.
• Understanding gender-based disparities in r-tPA administration is essential for equitable stroke care.
• Previous studies suggest potential gender differences in stroke treatment, necessitating further investigation.

Purpose of the Study:

• To investigate gender-specific differences in the application of r-tPA exclusion criteria within a stroke patient population.
• To identify clinical factors contributing to gender disparities in receiving r-tPA therapy.
• To enhance the understanding of factors influencing r-tPA eligibility in male and female stroke patients.

Main Methods:

• Analysis of ischemic stroke patients (aged 18+) from a healthcare system's stroke registry (2010-2013).
• Identification and comparison of r-tPA exclusion criteria between genders.
• Statistical analysis of clinical factors, including age, race, stroke severity, and contraindications.

Main Results:

• Of 633 eligible patients, 241 received r-tPA; 422 did not.
• No significant gender differences were found in warning signs or contraindications for r-tPA.
• Women aged over 80 were significantly more likely to be excluded from r-tPA compared to men (38% vs. 19%).

Conclusions:

• Exclusion criteria for r-tPA in stroke patients showed similarities between genders regarding race, stroke severity, and contraindications.
• Age emerged as a key differentiating factor, with older women facing higher exclusion rates for intravenous r-tPA.
• Absolute exclusion criteria included intracerebral hemorrhage and large infarcts, irrespective of gender.